PSPC1 knockout slows AML in preclinical models
Scientists at UT Health San Antonio have identified PSPC1 in mouse models as a promising new drug target for acute myeloid leukaemia (AML), a deadly blood cancer with limited treatment options.
List view / Grid view
News
New melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
Study identifies crucial gene behind metabolic liver disease
A team of researchers at Waseda University in Japan has identified a gene called Nwd1 that plays a key role in the development of metabolic dysfunction-associated steatohepatitis (MASH). This discovery could lead to new therapeutic strategies, potentially reshaping the treatment landscape for liver disease.
Alzheimer’s treatment targets root causes, not just symptoms
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
New study reveals how bacteria ‘vaccinate’ with viral DNA
The discovery from researchers at Johns Hopkins Medicine reveals how bacteria use the CRISPR-Cas system to store viral DNA, enhancing their immunity against future infections, and potentially paving the way for new phage-based therapies
B cell discovery could supercharge future vaccine development
New research reveals how B cells balance mutation and clonal expansion to refine their antibodies. This discovery could lead to more targeted and effective vaccine designs for various diseases.
New approach targets VHR enzyme for sepsis treatment
A new study reveals a promising approach to sepsis treatment by targeting the VHR enzyme using fragment-based drug discovery. This innovative method could lead to more effective therapies for sepsis and other immune-related conditions.
Drug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
Tract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
Novel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
New research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
Nanoparticle therapy shows potential to prevent spread of pancreatic cancer to liver
Pancreatic cancer is notoriously hard to treat, especially when it spreads to the liver in advanced stages. Researchers at UCLA’s California NanoSystems Institute (CNSI) have developed an innovative nanoparticle technology to tackle this challenge.
CeSPIACE: New peptide drug blocks COVID-19 variants
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
FairJourney Biologics acquires Charles River’s South San Francisco facility
FairJourney Biologics S.A., a global leader in antibody discovery and optimisation, has announced its acquisition of Charles River Laboratories’ South San Francisco site.
Beckman Coulter Life Sciences and Rarity Bioscience partner to advance oncology research
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
